test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/7737

Title: Original Article - Clinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes
Authors: Aaron, S.
Kumar, S.
Vijayan, J.
Jacob, J.
Alexander, M.
Gnanamuthu, C.
Keywords: Bone marrow smear, Vitamin B12 deficiency, Myeloneuropathy
Issue Date: 31-Dec-2005
Publisher: Medknow Publications on behalf of the Neurological Society of India
Citation: Neurology India (ISSN: 0028-3886) Vol 53 Num 1
Abstract: AIMS AND OBJECTIVES: To study the clinical and laboratory features of patients admitted with vitamin B12 deficiency-related (B12def) neurological syndromes. SETTINGS AND DESIGN: A hospital-based retrospective and prospective study conducted at a referral teaching hospital. MATERIALS AND METHODS: Consecutive patients admitted with vitamin B12deficiency-related neurological disorders during a three-year period from June 2000 to May 2003 were included. Data regarding clinical and laboratory features were obtained. Follow-up was done at least six months following treatment with parenteral vitamin B12. Chi-square test was used for statistical analysis. RESULTS: A total of 63 patients (52 males) with a mean age of 46.2 years were studied. The mean duration of symptoms at presentation was 10.3 months. Myeloneuropathy (54%) was the commonest neurological manifestation, followed by myeloneuropathy with cognitive dysfunction (34%), and peripheral neuropathy (9%). Neuropsychiatric manifestations and dementia were observed in 38% and 19% of patients respectively. All the patients had megaloblastic changes in the bone marrow smear. Eleven (17.5%) patients had both hemoglobin and the mean corpuscular volume (MCV) within the normal range. Follow-up after at least six months of therapy with parenteral B12 showed improvement in 54% patients. CONCLUSIONS: A high index of suspicion of B12def is required in patients presenting with myelopathy, cognitive decline, or neuropathy. A normal hemoglobin or MCV does not exclude B12def; therefore, other tests such as bone marrow smear and serum vitamin B12 assay are essential, as the condition is often reversible with treatment.
URI: http://hdl.handle.net/1807/7737
Other Identifiers: http://www.bioline.org.br/abstract?id=ni05014
Rights: Copyright 2005 Neurology India.
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
ni05014.pdf94.68 kBAdobe PDF
View/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft